Natrol Completes CetylPure Pilot Study

Natrol Inc. (Nasdaq:NTOL), a manufacturer and marketer of branded dietary supplements, today announced that results of a pilot study evaluating the active ingredient in its CetylPure(TM) product were positive and that, as a result, the company is planning a larger, more detailed clinical trial.

CetylPure(TM) is formulated to enhance joint health. The active proprietary blend tested was Cetyl Myristoleate Complex (CMC). The "complex" is significant because it contains a mixture of fatty acid esters that include Cetyl Myristoleate, which support joint health.

In the pilot study, women between the ages of 20 and 55 were selected. These women were tested during a four-week treatment period, and the results showed that for every standard test of efficacy that was measured in the trial, the group of women was found to have statistically improved physical activity. Many women also showed improved mood. These improvements continued for at least two weeks after the study even though CMC usage ceased.

"We are extremely pleased by the results of this pilot study," said Elliot Balbert, president and chairman of Natrol. "Our company is committed to helping people through the production of safe, efficacious products. This pilot study will be expanded through further clinical study as we work to find better ways to improve joint health."

About the arthritis-store Contact us

Disclaimer: Statements made, or products sold through this web site, have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure, or prevent any disease. If you have questions talk to your doctor or alternative medical practioner.

http://arthritis-symptom.com/

Jan	FEB	Mar
	12
2005	2006	2007